Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Consensus on optimal use of fixed-duration BTK inhibitor and venetoclax therapy in CLL: A delphi study comparing human expertise and AI methodologies

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMaria Rosaria VillaGNGiuseppe Rodolfo Nunziata

Discussion

Loading...

Member takes

Overview

Delphi consensus identified optimal BTK selection in CLL patients, indicating BTK inhibitors and personalized therapy roles.

Key Points

  • This research aims to establish consensus on the optimal use of fixed-duration BTK inhibitors in venetoclax therapy for CLL.
  • Panel of 9 hematologists conducted a Delphi study to develop consensus statements.
  • Key domains included patient-specific comorbidities, genetic risk profiles, and logistical considerations.
  • Consensus achieved through online voting with a four-point Likert scale to evaluate agreement.
  • 75% agreement was reached on ten out of twelve consensus statements.
  • Significant statements guide BTK selection, especially for elderly and unfit patients.
  • Cohen's kappa coefficient indicated low agreement (0.143) between expert and AI responses.

Cite This Study

Villa et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d503https://doi.org/10.1182/blood-2025-7434
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bridging Trials and Real Life in Fixed‐Duration <scp>BTKi</scp> –Venetoclax for <scp>CLL</scp> : A Delphi‐Enhanced Synthesis Incorporating Artificial Intelligence ( <scp>AI</scp> ) Benchmarks2026
  2. 2Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  3. 3Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025
  4. 4Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  5. 5Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma2025